SCHEMBL1764947

SCHEMBL1764947

COc1c(C=Cc2ccc(NS(C)(=O)=O)nc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.78
TRPV1 Q8NER1 4/20 0.35
PCSK9 Q8NBP7 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
CRBN Q96SW2 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
FYN P06241 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVR1 Q04771 1/20 0.31
LYN P07948 1/20 0.31
MAPK9 P45984 1/20 0.31
TUBB4A P04350 1/20 0.30
TUBB P07437 1/20 0.30
TUBA3C P0DPH7 1/20 0.30
TUBA1B P68363 1/20 0.30
TUBA4A P68366 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542447 1.00 CYP3A4 (0.78) CYP3A4TRPV1PCSK9PIK3CDPIK3CA
SCHEMBL1764858 0.94 CYP3A4 (0.70) CYP3A4TRPV1PCSK9PIK3CDPIK3CA
SCHEMBL2128077 0.88 CYP3A4 (1.00) CYP3A4TRPV1CRBNEGFRERBB2
SCHEMBL2128074 0.88 CYP3A4 (1.00) CYP3A4TRPV1CRBNEGFRERBB2
SCHEMBL1542737 0.87 CYP3A4 (0.71) CYP3A4TRPV1CRBNALPL
SCHEMBL2128959 0.87 CYP3A4 (0.71) CYP3A4TRPV1CRBNALPL
SCHEMBL2129430 0.87 CYP3A4 (0.59) CYP3A4TRPV1CRBN
SCHEMBL1543373 0.87 CYP3A4 (0.59) CYP3A4TRPV1CRBN
SCHEMBL1543595 0.85 CYP3A4 (0.65) CYP3A4EGFRERBB2TUBB4ATUBB
SCHEMBL1543597 0.85 CYP3A4 (0.65) CYP3A4EGFRERBB2TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8383824-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2013-02-26 US disclosed
EP-2501679-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-09-26 EP disclosed
WO-2011061243-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-26 WO disclosed
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123489-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HCCS, EIF2AK2, RNASE1 CYP3A4 60/4885TRPV1 4149/4885PCSK9 2475/4885
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885TRPV1 4645/4885PCSK9 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.